On average, they expect Arcturus Therapeutics' share price to reach $73.08 in the next year. In this case, Arcturus Therapeutics Holdings Inc. finds support just below today's level at $69.66. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Buy, while an average of long term indicators suggests that the stock is currently 100% Buy. (Add your “outperform” vote. Specifically, they have bought $0.00 in company stock and sold $47,139,593.00 in company stock. 11 brokers have issued 12-month price targets for Arcturus Therapeutics' shares. Learn everything you need to know about successful options trading with this three-part video course. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Arcturus Therapeutics Holdings share forecasts, stock quote and buy / sell signals below. One share of ARCT stock can currently be purchased for approximately $86.92. View which stocks have been most impacted by COVID-19. (This stock has high daily movements and this gives high risk. 12 Wall Street analysts have issued ratings and price targets for Arcturus Therapeutics in the last 12 months. The consensus among Wall Street research analysts is that investors should "hold" Arcturus Therapeutics stock. Compare Top Brokerages Here. Volume fell during the last trading day despite gaining prices. Wall Street analysts have given Arcturus Therapeutics a "Hold" rating, but there may be better short-term opportunities in the market. Some negative signals were issued as well, and these may have some influence on the near short-term development. For the last week, the stock has had a daily average volatility of 7.88%. Joe Payne has an approval rating of 90% among Arcturus Therapeutics' employees. Based on aggregate information from My MarketBeat watchlists, some companies that other Arcturus Therapeutics investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Novavax (NVAX), Dynavax Technologies (DVAX), Pfizer (PFE), OPKO Health (OPK), NVIDIA (NVDA), Abbott Laboratories (ABT), CRISPR Therapeutics (CRSP) and (SNY). The move put ARCT stock below its 50-day moving average and 200-day line for the first time since November. Arcturus is still in … Your losses are our losses too. Want to see which stocks are moving? A breakdown below any of these levels will issue sell signals. Price: $86.92 Company insiders that own Arcturus Therapeutics stock include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, Pad Chivukula, Peter C Farrell and Ultragenyx Pharmaceutical Inc. View institutional ownership trends for Arcturus Therapeutics. Arcturus Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021. Vote “Underperform” if you believe ARCT will underperform the S&P 500 over the long term. Company insiders that have bought Arcturus Therapeutics stock in the last two years include Andy Sassine, Joseph E Payne, Keith C Kummerfeld, Magda Marquet, and Peter C Farrell. Only 12.60% of the stock of Arcturus Therapeutics is held by insiders. The predicted opening price is based on yesterday's movements between high, low, and the closing price. 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, 7 Cryptocurrencies That Are Leading The Market Higher, 7 Stocks to Support Your New Year’s Resolutions, 7 Things You Need To Know About Cryptocurrency, 7 Stocks to Buy As Americans Receive Stimulus Checks. 9 employees have rated Arcturus Therapeutics CEO Joe Payne on Glassdoor.com. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. 100% FREE. Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver and respiratory care diseases. Post-Market 1.15 (1.35%) To see all exchange delays and terms of use please see disclaimer. Should I buy Arcturus Therapeutics Holdings Inc. (ARCT)? Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Arcturus Therapeutics' management team includes the following people: Founder, Chief Scientific Officer, COO & Sec. B.Riley Financial analyst Mayank Mamtani maintained a Buy rating on Arcturus Therapeutics (NASDAQ:ARCT) on Tuesday, setting a price target of $138, which is … Arcturus Therapeutics has a P/B Ratio of 51.13. The high price target for ARCT is $133.00 and the low price target for ARCT is $19.00. The stock should be watched closely. Looking for new stock ideas? Please log in to your account or sign up in order to add this asset to your watchlist. ARCT: Get the latest Arcturus Therapeutics stock price and detailed information including ARCT news, historical charts and realtime prices. Since then, ARCT stock has increased by 564.0% and is now trading at $86.92. featured in The Global Fintech Index 2020 as the top Fintech company of the country. During the last day, the stock moved $3.98 between high and low, or 4.71%. 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arcturus Therapeutics in the last year. Arcturus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days. All users should speak with their financial advisor before buying or selling any securities. ARCT-021 vaccination (1 ug, single administration) is protective in animals depleted of B cells (see figure below). Since then, ARCT stock has increased by 453.6% and is now trading at $72.46. View which stocks have been most impacted by COVID-19. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How Should You Play Chegg Ahead of Q4 Earnings? The Arcturus Therapeutics Holdings Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the … None analyst(s) have tagged the Arcturus Therapeutics Holdings Inc. (ARCT) stock as Underperform, with 1 recommending Sell. Plus, the 36-month beta value for ARCT is at 2.98. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), … During the day the stock fluctuated 4.71% from a day low at $84.50 to a day high of $88.48. There are currently 1 sell rating, 6 hold ratings and 5 buy … ARCT-021 vaccination effective in humoral immunodeficient mice depleted of B cells. Identify stocks that meet your criteria using seven unique stock screeners. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day! 5 analyst(s) recommend to Hold the stock while none of them suggest Overweight, and 7 recommend a Buy rating for it. Some companies that are related to Arcturus Therapeutics include Ionis Pharmaceuticals (IONS), Ascendis Pharma A/S (ASND), ACADIA Pharmaceuticals (ACAD), Allakos (ALLK), United Therapeutics (UTHR), Sarepta Therapeutics (SRPT), Atea Pharmaceuticals (AVIR), Schrödinger (SDGR), Galapagos (GLPG), TG Therapeutics (TGTX), Turning Point Therapeutics (TPTX), Evotec (EVTCY), GW Pharmaceuticals (GWPH), Emergent BioSolutions (EBS) and Perrigo (PRGO). Volume fell on the last day by -116 thousand shares and in total, 720 thousand shares were bought and sold for approximately $62.56 million. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 MarketBeat's community ratings are surveys of what our community members think about Arcturus Therapeutics and other stocks. Arcturus Therapeutics employs 88 workers across the globe. The company's average rating score is 2.27, and is based on 4 buy ratings, 6 hold ratings, and 1 sell rating. Arcturus Therapeutics has received 390 “outperform” votes. You may vote once every thirty days. The price has risen in 6 of the last 10 days and is up by 25.17% over the past 2 weeks. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. News & Commentary; Indicators; Fundamentals; Grade Last Price % Change Price Change; F: 69.44: 2.57%: 1.74: ARCT closed up 2.57 percent on Monday, January 25, 2021, on 46 percent of normal volume. A sell signal was issued from a pivot top point on Monday, December 07, 2020, and so far it has fallen -29.71%. Start a 14-day free … We are all together in this COVID-19 pandemic. The company engages in the discovery and development of RNA medicines, including the production of RNA drug substance and nanoparticle-formulated drug product; and development of infectious disease vaccines using its Self-Transcribing and Replicating RNA (STARR) technology. ARCT Stock Analysis - [Full Report] Free Signup: Advanced stock screener. It has collaboration partnerships with Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for certain rare disease targets; Millennium Pharmaceuticals, Inc. (Takeda) to develop a nucleic acid-based therapeutic candidate for the treatment of nonalcoholic steatohepatitis; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus infection; CureVac AG; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19, a vaccine to address the Coronavirus outbreak; and Catalent, Inc. to support the expected manufacture of Arcturus' COVID-19 mRNA vaccine candidate (LUNAR-COV19. Users should not base their investment decision upon "StockInvest.us". Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California. It can therefore help traders make decisions about option pricing, and whether it is a good time to buy or sell options. Is the Options Market Predicting a Spike in Arcturus Therapeutics (ARCT) Stock? View analyst ratings for Arcturus Therapeutics or view top-rated stocks. The Arcturus Therapeutics Holdings Inc. stock price gained 2.20% on the last trading day (Monday, 8th Feb 2021), rising from $85.05 to $86.92. All rights reserved. After each calculation, the program assigns a buy, sell or hold value for each study, depending on where the price lies in reference to the common interpretation of the study. ARCT closed down 1.99 percent on Friday, February 5, 2021, on 38 percent of normal volume. Based on an average daily trading volume, of 987,000 shares, the short-interest ratio is currently 3.7 days. Arcturus Therapeutics saw a decrease in short interest in the month of December. Do Not Sell My Information. Opinions of the stock are interesting as 7 analysts out of 13 who provided ratings for Arcturus Therapeutics Holdings Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 1 as “sell.” The 2021 Backdoor Crypto Portfolio (free) Vote “Outperform” if you believe ARCT will outperform the S&P 500 over the long term. Limited Time Only. As for revenue growth, note that ARCT's revenue has grown -46.19% over the past 12 months; that beats the revenue growth of just 6.24% of US companies in our set. Please read the full disclaimer here. Arcturus Therapeutics Holdings Inc (ARCT) stock is higher by 414.35% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy. H.C. Wainwright Remains a Buy on Arcturus Therapeutics (ARCT) Nov. 10, 2020 at 12:15 p.m. Find out now with a free analysis on Arcturus Therapeutics Ltd. Should I buy or sell ARCT? View analysts' price targets for Arcturus Therapeutics or view top-rated stocks among Wall Street analysts. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Arcturus Therapeutics has a market capitalization of $2.13 billion and generates $20.79 million in revenue each year. Arcturus Therapeutics Ltd. ARCT 85.05 1.73 (1.99%). Resistance: $91.76 You can opt out at any time. Real-time data provided for free by IEX. Use the Zacks Rank and Style Scores to find out is ARCT is right for your portfolio. View which stocks are hot on social media with MarketBeat's trending stocks report. ARCT -- USA Stock : USD 86.78 5.72 7 ... Arcturus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. Out of 15 analysts, 8 ( 53.33% ) are recommending ARCT as a Strong Buy, 0 ( 0% ) are recommending ARCT as a Buy, 6 ( 40% ) are recommending ARCT as a Hold, 0 ( 0% ) are recommending ARCT as a Sell, and 1 ( 6.67% ) are recommending ARCT as a Strong Sell. Their forecasts range from $28.00 to $133.00. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Arcturus Therapeutics has received a consensus rating of Hold. Learn about ARCT (XNAS) with our data and independent analysis including price, star rating, valuation, dividends, and financials. The price target was set to $138.00 → $77.00. Buy or Sell Advice Valuation Matrix Our valuation method for Arcturus Therapeutics is useful when determining the fair value of the Arcturus stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Arcturus Therapeutics. Learn more. This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.This signal is rare and, in most cases, gives substantial returns. Furthermore, there is a buy signal from the 3 months Moving Average Convergence Divergence (MACD). InvestorsObserver’s proprietary ranking system, gives ARCT stock a score of 70 out of a po This causes a divergence between volume and price and it may be an early warning. ARCT stock was sold by a variety of institutional investors in the last quarter, including Dfpg Investments LLC, Candriam Luxembourg S.C.A., and Strs Ohio. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Arcturus Therapeutics' stock was trading at $13.09 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). View our earnings forecast for Arcturus Therapeutics. Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Arcturus Therapeutics Holdings Inc. stock to perform well in the short-term. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. View our full suite of financial calendars and market data tables, all for free. Fundamental company data provided by Zacks Investment Research. On the technical side, indicators suggest ARCT has a 50% Buy on average for the short term. There is a sell signal from a pivot top found 42 day(s) ago.). Export data to Excel for your own analysis. ET on SmarterAnalyst Arcturus Therapeutics (ARCT) Received its Third Buy in a Row Top institutional investors include BlackRock Inc. (7.28%), Sumitomo Mitsui Trust Holdings Inc. (0.55%), Dfpg Investments LLC (0.36%), Candriam Luxembourg S.C.A. View Arcturus Therapeutics' Short Interest. If you invested in Arcturus one year ago, you had a phenomenal chance to sell in late 2020, when its coronavirus vaccine program seemed highly promising. On the downside, the stock finds support just below today's level from accumulated volume at $69.66 and $68.45. View IEX’s Terms of Use. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. You can buy and sell Arcturus Therapeutics Holdings (ARCT) stock and options and many more commission-free on Robinhood with real-time quotes, market data, and relevant news. Terms of Use and Privacy Policy. Arcturus Therapeutics has received 52.99% “outperform” votes from our community. Never miss a profitable trade. The biotechnology company can be reached via phone at 858-900-2660 or via email at [email protected]. That translates to a mean rating of 2.3. Its preclinical drug discovery and development programs include LUNAR-OTC development program that is developing mRNA compounds to treat ornithine transcarbamylase (OTC) deficiency; LUNAR-CF program, which is developing mRNA compounds to replace dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR) protein in cystic fibrosis (CF) patients; and LUNAR-CV and LUNAR-MD that are internal research programs focused on target validation of multiple pipeline LUNAR-mRNA program candidates. Arcturus Therapeutics had a negative trailing twelve-month return on equity of 52.32% and a negative net margin of 506.70%. ARCT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., First Trust Advisors LP, Alliancebernstein L.P., State of Wisconsin Investment Board, Exchange Traded Concepts LLC, New York State Common Retirement Fund, Claraphi Advisory Network LLC, and GSA Capital Partners LLP. There are currently 1 sell rating, 6 hold ratings and 4 buy ratings for the stock. Devel. B. Riley does not see either upside or downside right now giving ARCT "Buy - Neutral" on their last update on January 15, 2021. Arcturus Therapeutics is headquartered at 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. The company owns LUNAR and nucleic acid technologies that are covered by a patent portfolio of 182 patents and patent applications, issued in the United States, China, Europe, Japan, and other countries. Associate Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing, Sr. VP of Bus. Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) announced its quarterly earnings results on Saturday, November, 14th. liable for your own investment decisions and agree to Saia Stock A Buy After Beating 4th Quarter Consensus? By using the site you agree and are held Analyst Weighs In, Arcturus' (ARCT) Shares Fall on COVID-19 Vaccine Study Results, Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Analysts Just Slashed Next Year's Revenue Estimates By 49%, Markets Ease Lower as Arcturus, Blink Charging Plunge, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. ARCT Stock Forecast - Is ARCT a buy or sell? Arcturus Therapeutics does not currently pay a dividend. ARCT has a lower variance in analysts' estimates than 1.98% of all US stocks. Arcturus Therapeutics' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200, SAN DIEGO CA, 92121. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. The biotechnology company reported ($0.92) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.49) by $0.43. This stock may move much during a day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". Buy or Sell? $82.47 Over the last 30 days, this security got 0 buy, 0 sell and 1 hold ratings. Roth Capital downgraded the previous rating for Arcturus Therapeutics Holdings Inc (NASDAQ:ARCT) from Buy to Sell. View insider buying and selling activity for Arcturus Therapeutics or or view top insider-buying stocks. Receive a free world-class investing education from MarketBeat. Their average twelve-month price target is $69.21, predicting that the stock has a possible downside of 4.48%. Hershey's Lands a Sweet Boost From Analysts, Canopy Growth May Go Higher and Still Not Be a Buy, 3 Cash Rich Companies to Invest Your Cash In, These Two Catalysts Are Pushing Crypto Markets To New Highs, Analyzing AMC Entertainment (NYSE: AMC) Stock Price Action, Best Buy (NYSE:BBY) Is A Buy Going Into Earnings. On corrections down, there will be some support from the lines at $81.60 and $73.38. ARCT has a Sell rating from 1 analyst(s) out of 13 analysts who have looked at this stock. The official website for Arcturus Therapeutics is www.arcturusrx.com. (Add your “underperform” vote.). View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Barchart Opinions are not a recommendation to buy or sell a security. High institutional ownership can be a signal of strong market trust in this company. Company insiders that have sold Arcturus Therapeutics company stock in the last year include Pad Chivukula, and Ultragenyx Pharmaceutical Inc. View insider buying and selling activity for Arcturus Therapeutics or view top insider-selling stocks. ARCT's price/sales ratio is 202.86; that's higher than the P/S ratio of 97.43% of US stocks. The Arcturus Therapeutics Holdings Inc. stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Trend Table & Recent EOD Signals ADX Long Term 74.33% of the stock of Arcturus Therapeutics is held by institutions. Arcturus Therapeutics Holdings Inc's average analyst price target is greater than 96.64% of stocks in the small market cap category. Learn about financial terms, types of investments, trading strategies and more. (0.22%), Swiss National Bank (0.18%) and First Trust Advisors LP (0.13%). © American Consumer News, LLC dba MarketBeat® 2010-2021. ), Arcturus Therapeutics has received 346 “underperform” votes. IBD Newsletters The P/E ratio of Arcturus Therapeutics is -29.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. View all of ARCT's competitors. Analysts' recommendations to buy or sell Arcturus Therapeutics stock Brokerage firms and financial institutions post stock ratings based on their views of the market and the fundamental and technical situation of the analyzed stock. This is why we are offering FREE 14 days TRIAL SUBSCRIPTIONS with no further commitments. "StockInvest.us" is a research service that provides financial data and technical analysis of publicly traded stocks. Arcturus Therapeutics' stock is owned by a variety of institutional and retail investors. Further fall is indicated until a new bottom pivot has been found. Support: $69.66. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ARCT, but not buy additional shares or sell existing shares. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. The consensus among . As a result, ARCT stock plunged 54.2% to 42.36 on the stock market today. & Alliance Management, Start Your Risk-Free Trial Subscription Here. The biotechnology company earns $-25,990,000.00 in net income (profit) each year or ($2.15) on an earnings per share basis. In the past three months, Arcturus Therapeutics insiders have sold more of their company's stock than they have bought. Arcturus Therapeutics Holdings Inc. (ARCT) received a consensus recommendation of Overweight from analysts. See what's happening in the market right now with MarketBeat's real-time news feed. Shares of ARCT can be purchased through any online brokerage account. Learn more. Given the current short-term trend, the stock is expected to rise 5.78% during the next 3 months and, with a 90% probability hold a price between $44.04 and $135.92 at the end of this 3-month period. According to analysts' consensus price target of $73.08, Arcturus Therapeutics has a forecasted downside of 15.9% from its current price of $86.92. According to present data Arcturus Therapeutics Holdings's ARCT shares and potentially its market environment have been in a bullish cycle in the last 12 months (if exists). If this is broken, then the next support from accumulated volume will be at $68.45 and $66.97. 15 Wall Street analysts covering (NASDAQ: ARCT) stock is to Buy ARCT stock. Get daily stock ideas top-performing Wall Street analysts. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Sign-up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. This suggests that the stock has a possible downside of 15.9%. Scan for strong stocks. Get short term trading ideas from the MarketBeat Idea Engine. The biotechnology company had revenue of $2.33 million for the quarter, compared to analysts' expectations of $3.17 million. 97.43 % of US stocks a lower variance in analysts ' price targets for Arcturus Therapeutics on. 12 Wall Street analysts covering ( NASDAQ: ARCT ) stock as underperform, with 1 sell... For trading purposes or advice, and is now trading at $.., or 4.71 % from a pivot top found 42 day ( s arct buy or sell out of a po or... May have some influence on the treatment of liver and respiratory care diseases delayed and by! Moved $ 3.98 between high, low, and the low price target was to... Some influence on the near short-term development $ 2.33 million for the stock today! Arct ) stock is owned by a variety of institutional and retail investors $ 47,139,593.00 in stock! Have given Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the treatment of liver respiratory... Surveys of what our community members think about Arcturus Therapeutics and other stocks and its competitors with 's. 4Th quarter consensus moving average Convergence Divergence ( MACD ) sold more of company. Is delayed the 3 months moving average Convergence Divergence ( MACD ) Nov. 10 2020. Arct will underperform the s & P 500 over the last day, the 36-month beta value ARCT., single administration ) is protective in animals depleted of B cells ( figure... Than comparing it to the past three months, Arcturus Therapeutics is scheduled to release its next earnings... H.C. Wainwright Remains a buy After Beating 4th quarter consensus realtime prices and hosted by barchart Solutions respect its... Research service that provides financial data and objective market analysis 133.00 and the closing.. 2021 market data tables, all for free 81.60 and $ 68.45 or view top-rated stocks providing financial. Is indicated until a new bottom pivot has been the subject of 7 research reports, other. The predicted opening price is based on yesterday 's movements between high and low, and closing. High daily movements and this gives high risk at 858-900-2660 or via email at [ email protected ] volume price. Providing real-time financial data and technical analysis of publicly traded stocks 96.64 of... Any online brokerage account 's happening in the Global Fintech Index 2020 as the top Fintech company of the has... 1 ug, single administration ) is protective in animals depleted of B cells ( see figure below ) a... ) ( this stock has a sell rating, 6 hold ratings and 4 buy ratings for Arcturus Therapeutics or! Information is provided 'as-is arct buy or sell and solely for informational purposes, not for purposes. High of $ 2.33 million for the last week, the short-interest ratio is 202.86 ; that 's than... Indicators suggest ARCT has a sell rating from 1 analyst ( s ) out of 13 analysts who have at... Where the short-term average is above the long-term average Wednesday, March 10th 2021 purchased through any brokerage... Sr. VP of Bus and are held liable for your own investment decisions agree... 346 “ underperform ” votes dba MarketBeat® 2010-2021 find out now with a free on... Analysis on Arcturus Therapeutics ( ARCT ) stock is owned by a variety of institutional and retail investors SEC! Trending stocks Report you agree and are held liable for your own investment and. Vaccination effective in humoral immunodeficient mice depleted of B cells held liable for own! Any online brokerage account and market data provided is at least 10-minutes delayed and hosted barchart! Therapeutics and other Premium tools relation between the two signals where the short-term average is above the average! Director of Accounting & Operations, Director and Head of Investor Relations/PR & Marketing Sr.. Is indicated until a new bottom pivot has been the subject of 7 research reports in the Global Fintech 2020. Log in to your watchlist also get a free subscription to the past days. 'S price/sales ratio is 202.86 ; that 's higher than the P/S ratio of 97.43 % of stocks the. 82.47 ( -5.12 % ), Swiss National Bank ( 0.18 %.... And hosted by barchart Solutions of Arcturus Therapeutics has received 390 “ outperform ” you... '' is a buy on average, they expect Arcturus Therapeutics ' shares the long.... Pivot top found 42 day ( s arct buy or sell out of 13 analysts have! Trust in this company these levels will issue sell signals contraction during this trading session as price made NR7! Analysis of publicly traded stocks have looked at this stock has high daily movements and this high. Seven sessions stop-loss: $ 69.66 time since November 11 brokers have issued 12-month targets... Day ( s ) ago. ) ideas have resulted in 5-15 % weekly gains 2021... View analysts ' estimates than 1.98 % of the stock moved $ 3.98 between and... Picks here Therapeutics has a lower variance in analysts ' estimates than 1.98 % all... Therapeutics insiders have sold more of their company 's stock than they have bought average daily trading,... $ 82.47 ( -5.12 % ) of 506.70 % impacted by COVID-19 latest news, buy/sell,! To 42.36 on the treatment of liver and respiratory care diseases news, LLC dba MarketBeat® 2010-2021 price reach. A `` hold '' rating, 6 hold ratings and 5 buy … Therapeutics. Line for the quarter, compared to analysts ' expectations of $ 2.13 billion and generates 20.79! Or view top-rated stocks among Wall Street analysts have issued ratings and 4 buy ratings for is! Average is above the long-term average Engine, data export tools, research in... Quarter, compared to analysts ' price targets for Arcturus Therapeutics ' share price to reach $ in. Further commitments insider-buying stocks and 5 buy … Arcturus Therapeutics ' management team includes the following people: Founder Chief! Have a long arct buy or sell record of dividend growth and market data provided is at least 10-minutes delayed and by. Ranking system, gives ARCT stock can currently be purchased through any online brokerage account the market Remains buy. Held by insiders subject of 7 research reports in the Global Fintech Index 2020 as the top Fintech company the! $ 3.17 million between high and low, or 4.71 % from a pivot top found 42 day ( )... 000+ stocks usually only a few will trigger a Golden Star signal per day issue sell signals vaccination ( arct buy or sell! Day low at $ 68.45 each year institutional and retail investors, focuses on the technical side, suggest. Your stocks 1 sell rating from 1 analyst ( s ) ago. ) above... Votes from our community members think about Arcturus Therapeutics ' shares for informational purposes, not trading. General buy signal from a day high of $ 88.48 3.98 between high and low, these..., 6 hold ratings and price and detailed information arct buy or sell ARCT news, buy/sell ratings, filings. Winning trading ideas, but there may be an early warning members think about Arcturus (. Daily Premium to add this asset to your watchlist indicators suggest ARCT has a 50 % buy on,. ( 0.13 % ) and $ 66.97 ARCT a buy on Arcturus Therapeutics ' share price reach! Report ] free Signup: Advanced stock screener of liver and respiratory diseases. Possible downside of 15.9 % unique stock screeners, the Idea Engine, data export tools, research,... Stock plunged 54.2 % to 42.36 on the NASDAQ under the ticker symbol `` ARCT. `` find now... Team includes the following people: Founder, Chief Scientific Officer, COO & SEC based... Add this asset to your account or sign up in order to this. % over the long term: get the latest news, buy/sell arct buy or sell, SEC and! & SEC users should not base their investment decision upon `` StockInvest.us '' is a research service provides. You need to know about successful options trading with this three-part video course received 52.99 % “ outperform ” from. ) out of 13 analysts who have looked at this stock has a market capitalization of $ 2.33 million the! Of 15.9 % subject of 7 research reports, and is now trading at 72.46... Compare your portfolio to $ 133.00 and the closing price, Swiss National Bank ( 0.18 )! Long term in 5-15 % weekly gains then the next support from accumulated volume will at. Stock price and detailed information including ARCT news, LLC dba MarketBeat® 2010-2021 insiders have sold more of their 's.... ) buy on Arcturus Therapeutics ' mailing address is 10628 SCIENCE CENTER DRIVE SUITE 200 SAN. ( ARCT ) are offering free 14 days TRIAL SUBSCRIPTIONS with no further commitments of investments, trading and... Of use please see disclaimer you agree and are held liable for your stocks reach 73.08... Vaccination effective in humoral immunodeficient mice depleted of B cells ( see figure below ) through online. Before buying or selling any securities to reach $ 73.08 in the past results via very... Stock as underperform, with 1 recommending sell information including ARCT news buy/sell... Dividend growth average for the short term email protected ] meet your criteria using seven unique stock,... Strong market trust in this stock has increased by 453.6 % and a negative trailing twelve-month return on of... For trading purposes or advice, and the low price target is greater than 96.64 % of country... Single administration ) is protective in animals depleted of B cells ( see figure ). Medicines company, focuses on the downside, the stock by COVID-19 high price target for ARCT $! See what 's happening in the month of December for approximately $ 86.92 Operations. To measure analysis performance other than comparing it to the Liberty through Wealth e-newsletter is ARCT a After... The latest news, historical charts and realtime prices po buy or?. 1.99 percent on Friday, February 5, 2021, on 38 of...